Small animal PET in oncology: the road from bench to bedside.

Positron emission tomography (PET) is routinely performed in patients with cancer for disease staging, assessment of relapse, and evaluation of therapy response. In addition to its well-established value in human malignant diseases, the use of special small animal PET (SA-PET) scanners have allowed for accurate assessment of small animals bearing human tumors. This application of PET provides whole-body, noninvasive, functional data of tumor lesions and can be used to assess abnormalities in the metabolic pathways of cancer, such as uncontrolled proliferation, increased apoptosis, and angiogenesis. Several positron-emitting tracers labeled with 18-fluorine and 11-carbon are currently available for PET studies to image abnormal biologic pathways of tumors. Moreover, SA-PET can be used to evaluate tumor-cell-receptor expression, a sign of tumor cells differentiation that is relevant for planning targeted therapies. Another advantage of SA-PET is the quantitation capability: Semiquantitation of the tumor activity can be performed at each scan and compared in the same animal over time to monitor tumor growth or to assess the response to new therapies. This review focuses on the applications of SA-PET for the visualization of the pathophysiologic pathways of tumor cells.

[1]  C. Reutelingsperger,et al.  Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. , 1998, Cytometry.

[2]  J. Schellens,et al.  Application of PET/CT in the development of novel anticancer drugs. , 2008, The oncologist.

[3]  V. Grégoire,et al.  Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  R. Coleman,et al.  Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. , 2002, The Journal of urology.

[5]  Sanjiv S Gambhir,et al.  Preclinical Efficacy of the c-Met Inhibitor CE-355621 in a U87 MG Mouse Xenograft Model Evaluated by 18F-FDG Small-Animal PET , 2007, Journal of Nuclear Medicine.

[6]  H. Jin,et al.  Integrins: roles in cancer development and as treatment targets , 2004, British Journal of Cancer.

[7]  G. Hutchins,et al.  [11C]Choline as a PET biomarker for assessment of prostate cancer tumor models. , 2004, Bioorganic & medicinal chemistry.

[8]  Y. Nishiyama,et al.  Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  M. Phelps,et al.  Evaluation of [18F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[11]  P. Price,et al.  The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  P. Black,et al.  αvβ3 and αvβ5 Integrin Expression in Glioma Periphery , 2001 .

[13]  Robert M. Lewitt,et al.  Application of the row action maximum likelihood algorithm with spherical basis functions to clinical PET imaging , 2001 .

[14]  S. Gambhir,et al.  Molecular imaging in living subjects: seeing fundamental biological processes in a new light. , 2003, Genes & development.

[15]  J. Bading,et al.  Imaging of Cell Proliferation: Status and Prospects , 2008, Journal of Nuclear Medicine.

[16]  M. Mintun,et al.  Breast cancer: PET imaging of estrogen receptors. , 1988, Radiology.

[17]  Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  M. Salto‐Tellez,et al.  Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. , 2008, Journal of hepatology.

[19]  FDG small animal PET permits early detection of malignant cells in a xenograft murine model , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  W. Oyen,et al.  Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide. , 2007, Nuclear medicine and biology.

[21]  V. Ambrosini,et al.  18F-FDG small animal PET for early detection of human anaplastic large cells lymphoma xenograft in immunocompromised mice. , 2008, Anticancer research.

[22]  R. Rosell,et al.  Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. , 2002, Biochemical and biophysical research communications.

[23]  Sanjiv S Gambhir,et al.  PET of vascular endothelial growth factor receptor expression. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  Sanjiv S. Gambhir,et al.  Reproducibility of 18F-FDG microPET Studies in Mouse Tumor Xenografts , 2007, Journal of Nuclear Medicine.

[25]  Richard L Wahl,et al.  "USA-Fat": prevalence is related to ambient outdoor temperature-evaluation with 18F-FDG PET/CT. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[27]  Marc C. Huisman,et al.  Performance evaluation of the Philips MOSAIC small animal PET scanner , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  H. Hollema,et al.  In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft , 2007, Journal of Nuclear Medicine.

[29]  W. Oyen,et al.  Improved targeting of the αvβ3 integrin by multimerisation of RGD peptides , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  A. Unterberg,et al.  Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. , 2006, Cancer treatment reviews.

[31]  Otto Muzik,et al.  Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.

[32]  U Ruotsalainen,et al.  Influence of the blood glucose concentration on FDG uptake in cancer--a PET study. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  L. Buie,et al.  Bevacizumab: A Treatment Option for Recurrent Glioblastoma Multiforme , 2008, The Annals of pharmacotherapy.

[34]  S. Gambhir,et al.  Quantitative PET Imaging of Tumor Integrin αvβ3 Expression with 18F-FRGD2 , 2006 .

[35]  Chandra L. Theesfeld,et al.  Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[36]  S. Siegel,et al.  Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[37]  M. Schwaiger,et al.  Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  F. Khuri,et al.  Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer. , 2006, Oncology.

[39]  V. Ambrosini,et al.  Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours , 2007, Nuclear medicine communications.

[40]  L. Specht,et al.  PET/CT in the management of haematological malignancies , 2008, European journal of haematology.

[41]  William Pao,et al.  Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Robert J. Gillies,et al.  Causes and Consequences of Increased Glucose Metabolism of Cancers , 2008, Journal of Nuclear Medicine.

[43]  O. Mawlawi,et al.  Evaluation of 2′-deoxy-2′-[18F]fluoro-5-methyl-1-β-l-arabinofuranosyluracil ([18F]-l-FMAU) as a PET imaging agent for cellular proliferation: comparison with [18F]-d-FMAU and [18F]FLT , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[44]  Roger Lecomte,et al.  Breast cancer models to study the expression of estrogen receptors with small animal PET imaging. , 2004, Nuclear medicine and biology.

[45]  Jinha M. Park,et al.  Reproducibility of 3'-deoxy-3'-(18)F-fluorothymidine microPET studies in tumor xenografts in mice. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[46]  A. Alavi,et al.  Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies , 2007, Nuclear medicine communications.

[47]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[48]  H. Minn,et al.  Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[49]  R. Coleman.  Value of FDG-PET scanning in management of lung cancer , 2002, The Lancet.

[50]  V. Ambrosini,et al.  Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. , 2008, Cancer treatment reviews.

[51]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[52]  S. Larson,et al.  Molecular Imaging of EGFR Kinase Activity in Tumors with 124I-Labeled Small Molecular Tracer and Positron Emission Tomography , 2006, Molecular Imaging and Biology.

[53]  T J Spinks,et al.  The design and physical characteristics of a small animal positron emission tomograph. , 1995, Physics in medicine and biology.

[54]  D Malakoff,et al.  The Rise of the Mouse, Biomedicine's Model Mammal , 2000, Science.

[55]  C. Kumar.  Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. , 2003, Current drug targets.

[56]  A. Krüger,et al.  O-(2-[18F]Fluoroethyl)-L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[57]  R L Wahl,et al.  Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[58]  C. Copie-Bergman,et al.  [F-18]-Fluoro-2-deoxy-d-glucose positron emission tomography as a tool for early detection of immunotherapy response in a murine B cell lymphoma model , 2007, Cancer Immunology, Immunotherapy.

[59]  V. Sossi,et al.  Micropet imaging: in vivo biochemistry in small animals , 2005, Journal of Neural Transmission.

[60]  Young Joo Kim,et al.  Preparation of a Promising Angiogenesis PET Imaging Agent: 68Ga-Labeled c(RGDyK)–Isothiocyanatobenzyl-1,4,7-Triazacyclononane-1,4,7-Triacetic Acid and Feasibility Studies in Mice , 2008, Journal of Nuclear Medicine.

[61]  Jeih-San Liow,et al.  Evaluation of anesthesia effects on [18F]FDG uptake in mouse brain and heart using small animal PET. , 2004, Nuclear medicine and biology.

[62]  Marianne Patt,et al.  [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. , 2003, Nuclear medicine and biology.

[63]  Torsten Mattfeldt,et al.  Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[64]  D. Hunting,et al.  PET imaging of apoptosis with 64Cu-labeled streptavidin following pretargeting of phosphatidylserine with biotinylated annexin-V , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[65]  J. Kaanders,et al.  The hypoxic tumour microenvironment, patient selection and hypoxia-modifying treatments. , 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

[66]  Jurgen Seidel,et al.  Performance evaluation of the GE healthcare eXplore VISTA dual-ring small-animal PET scanner. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[67]  Michael E Phelps,et al.  Impact of animal handling on the results of 18F-FDG PET studies in mice. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[68]  Qimin He,et al.  3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. , 2003, Cancer research.

[69]  H. Wakelee,et al.  Role of Anti-angiogenesis Agents in Treating NSCLC: Focus on Bevacizumab and VEGFR Tyrosine Kinase Inhibitors , 2007, Current treatment options in oncology.

[70]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[71]  L. Wiens,et al.  Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[72]  C. Reutelingsperger,et al.  The Complexity of the Phospholipid Binding Protein Annexin V , 1995, Thrombosis and Haemostasis.

[73]  Roland Hustinx,et al.  Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[74]  James F. Young,et al.  MicroPET: a high resolution PET scanner for imaging small animals , 1996, IEEE Nuclear Science Symposium Conference Record.

[75]  J. Bading,et al.  Pharmacokinetics of the thymidine analog 2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (FMAU) in tumor-bearing rats. , 2004, Nuclear medicine and biology.

[76]  Michel Defrise,et al.  Exact and approximate rebinning algorithms for 3-D PET data , 1997, IEEE Transactions on Medical Imaging.

[77]  C. Geyer,et al.  Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma , 2005, Cancer.

[78]  Craig K Abbey,et al.  In vivo positron-emission tomography imaging of progression and transformation in a mouse model of mammary neoplasia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[79]  David A. Cheresh,et al.  Definition of Two Angiogenic Pathways by Distinct αv Integrins , 1995, Science.

[80]  V. Grégoire,et al.  Detection of tumour hypoxia: comparison between EF5 adducts and [18F]EF3 uptake on an individual mouse tumour basis , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[81]  Nobuyuki Oyama,et al.  18F-fluoroacetate: a potential acetate analog for prostate tumor imaging--in vivo evaluation of 18F-fluoroacetate versus 11C-acetate. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[82]  Mark Muzi,et al.  In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[83]  H. Sakahara,et al.  Evaluation of 3'-deoxy-3'-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[84]  Simon R Cherry,et al.  Small-animal preclinical nuclear medicine instrumentation and methodology. , 2008, Seminars in nuclear medicine.

[85]  Jurgen Seidel,et al.  Resolution uniformity and sensitivity of the NIH ATLAS small animal PET scanner: comparison to simulated LSO scanners without depth-of-interaction capability , 2001 .

[86]  I. Ziv,et al.  Molecular imaging of cell death in vivo by a novel small molecule probe , 2006, Apoptosis.